TORONTO, Sept. 27, 2017 /CNW/ - Canopy Health Innovations
("Canopy Health" or "CHI"), the partly-owned biopharmaceutical
research and development subsidiary of Canopy Growth Corporation
(TSX: WEED) ("Canopy Growth"), today announced that it has filed
nine provisional patents pertaining to the applications of cannabis
and cannabinoid based therapeutics in sleep and related nervous
system disorders.
The filing is part of a concerted plan to bring to patients and
healthcare providers innovative medicines and health products
targeting disease areas with substantial medical needs. As part of
this plan, Canopy Health is collaborating with respected
world-class academic researchers and clinicians, and working with
leading research organizations and regulators in jurisdictions of
interest to develop and register these breakthrough products.
Sleep disorders are considered to be severely undertreated and
are often conduits to equally serious and debilitating psychiatric
and neurological conditions.
"The cannabis industry is an industry with centuries of
anecdotal evidence, but limited in deep and credible scientific
research," said Bruce Linton,
Chairman & CEO, Canopy Growth. "By enabling world-class
research, we are confident that we can contribute to an increased
understanding of cannabis as an effective and safe method of
treatment and create products that will improve lives. Sleep
presents a first opportunity for Canopy Health to advance in this
direction, with more soon to follow."
Canopy Health has filed nine provisional patents in the United States, which is common practice in
the field of intellectual property generation and protection.
Patents are first filed in the United
States to create a priority date and allow for future
filings in other selected jurisdictions, including Canada. Although cannabis is not presently
federally legal in the United
States, intellectual property generation and protection
activity pertaining to cannabis and cannabinoids has dramatically
accelerated there over the past few years.
In tandem with the recent provisional patent filings, Canopy
Health, including its wholly owned subsidiary Canopy Animal Health
has closed additional funding through sales of common shares
bringing total funds raised to date for Canopy Health to over CDN
$15.8 million. Capital was secured
through new and existing shareholders, including $4 million from Canopy Growth. These funds will
be used to advance research and product development with the
objective of ultimately bringing them to patients and healthcare
providers worldwide.
Here's to Future Growth.
About Canopy Health Innovations:
Canopy Health
Innovations (Canopy Health) operates as an independent and private
collaborator of Canopy Growth Corporation and its subsidiaries.
Canopy Health is owned in part by Canopy Growth and qualified
private investors. Canopy Health's business model is to engage
simultaneously in numerous research areas, with a strict focus on
the creation and enhancement of intellectual property, which is
then retained exclusively on a first-priority basis. Canopy Growth
and its subsidiaries retain an exclusive, first priority right to
license and commercialize intellectual property developed and owned
by Canopy Health.
Canopy Health is focused on providing more in depth and advanced
understanding of the cannabis plant and the potential medical uses
for both humans and animals. This, combined with a more favourable
regulatory system, and a global paradigm shift towards the
normalization of cannabis, positions Canopy Health as an ideal
company to invest in, conduct research, and develop safe,
effective, natural medicines derived from cannabis.
About Canopy Growth
Canopy Growth is a world-leading diversified cannabis company,
offering distinct brands and curated cannabis varieties in dried,
oil and capsule forms. Through its wholly‑owned subsidiaries,
Canopy Growth operates numerous state-of-the-art production
facilities with over half a million square feet of GMP-certified
indoor and greenhouse production capacity, all to an unparalleled
level of quality assurance procedures and testing. Canopy Growth
has established partnerships with leading sector names in
Canada and abroad, with interests
and operations spanning four continents. The Company is
proudly dedicated to educating healthcare practitioners, providing
consistent access to high quality cannabis products, conducting
robust clinical research, and furthering the public's understanding
of cannabis. For more information visit www.canopygrowth.com.
Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but
not always, forward-looking statements can be identified by the use
of words such as "plans", "expects" or "does not expect", "is
expected", "estimates", "intends", "anticipates" or "does not
anticipate", or "believes", or variations of such words and phrases
or state that certain actions, events or results "may", "could",
"would", "might" or "will" be taken, occur or be achieved.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of Canopy Growth Corporation, Tweed
Inc., Tweed Farms Inc. or Bedrocan Canada Inc. to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Examples of
such statements include future operational and production capacity,
the impact of enhanced infrastructure and production capabilities,
and forecasted available product selection. The forward-looking
statements included in this news release are made as of the date of
this news release and Canopy Growth Corp. does not undertake an
obligation to publicly update such forward-looking statements to
reflect new information, subsequent events or otherwise unless
required by applicable securities legislation.
Neither the TSX Exchange nor its Regulation Services Provider
(as that term is defined in policies of the TSX Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Canopy Growth Corporation